Antiplaque/antigingivitis OTC Review
This article was originally published in The Tan Sheet
Executive Summary
Final formulation testing requirement assessment on case-by-case basis for ingredients/combos included in final category monograph recommended by the NDMA/CTFA Oral Care Task Group in May 19 comments to FDA. A variety of in vitro and in vivo studies, ranging from animal tests to human clinicals, may be appropriate tests, the group says, adding it is the responsibility of companies to provide the testing rationale. The task group plans to present its recommendations for final formulation testing, labeling and combo products at FDA's NDAC Plaque Subcommittee meeting May 27-29. The committee discussed case-by-case standards for final formulation testing at its last meeting in October ("The Tan Sheet" Nov. 3, 1997, p. 6)...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning